Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jan 18, 2018 in Melanoma | 0 comments

In a nutshell

This study examined the long-term effectiveness of vemurafenib (Zelboraf) as treatment for BRAF-mutant metastatic melanoma. Researchers concluded that vemurafenib is associated with improved overall survival. 

Some background

Over 50% of melanoma patients has a mutation (permanent change) in the BRAF gene. This can increase tumor aggressiveness. Vemurafenib is a BRAF inhibitor. This targeted therapy can block cancer growth, improving patient survival.

A prior study suggested that after 1 year patients treated with vemurafenib had an improved survival when compared to patients treated with dacarbazine (DTIC-Dome). It is not clear if this treatment is still associated with better outcomes after an extended follow-up period.  

Methods & findings

The objective of this study was to investigate the outcomes of advanced melanoma patients after treatment with vemurafenib. 675 patients were randomly assigned to receive vemurafenib (337; group 1) or dacarbazine (338; group 2). 

Progression-free survival (PFS; time from treatment to cancer progression) and overall survival (OS; time from treatment to death by any cause) were measured.

At 2 years, OS was 30% for group 1 and 24% for group 2. At 3 years, OS was 21% for group 1 and 19% for group 2. At a follow up of 4 years the OS rates for patients from group 1 were 17% and 16% for patients from group 2.

84 patients from group 2 switched to treatment with vemurafenib during follow-up. 52% of group 1 and 51% of group 2 received further anti-cancer treatment.

The bottom line

This study suggested that vemurafenib is associated with an improved tumor response in the long-term.

The fine print

This study was funded by F. Hoffmann – La Roche Ltd, the producer of vemurafenib.

Published By :

Annals of oncology : official journal of the European Society for Medical Oncology

Date :

Oct 01, 2017

Original Title :

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

click here to get personalized updates